Crescendo launches to gather broader range of real-world data

Crescendo Health was launched with an initial investment of $3.4m (€3.1m) from early-stage investors, and is classified as a public benefit corporation, which are corporations that are for profit but created to generate social and public good.

The company outlined that it provides tools and support to biopharma, medical device manufacturers and clinical research organizations (CROs) to collect and integrate information from patients’ clinical care.

The idea being to take the health data generated by patients outside of clinical research, alongside the data generated in trials, to give a broader understanding of their reaction to treatments. Crescendo states that this will help trial sponsors to advance therapies in a more efficient and cost-effective way.

In return, the patients will be able to access, through Crescendo personal health application, all of their health records, with the data encrypted to provide security.

With the patients’ consent, this data can then be shared with the research study that the individual is partaking in. Crescendo notes that at the end of a study, the participant is able to maintain access to their health record or request for the personal data to be deleted.

“To date, these external real-world data elements weren’t accessible to trial sponsors at scale, which is why we’re building the machinery and support required to change the paradigm. We are working towards a future where research is seamlessly integrated with routine clinical care, making participation easy and accessible for patients from all backgrounds,”​ said Sam Roosz, co-founder and CEO of Crescendo Health.

For trial sponsors, Crescendo suggests that having data from a patient’s ‘healthcare journey’ can reveal the true cost of their care. The company also outlines that it can provide post-marketing observational studies or safety registries, and long-term follow-up or observational extension studies to understand the impact of treatments over time.

According to Crescendo, this service will help fill the gaps for study sponsors once the study participants are beyond the clinical research setting, such as in primary care, emergency department visits, lab tests, and prescription fills.

Define Ventures, one of the investors in the organization, noted that Crescendo’s approach will dovetail with the rise of decentralized trials​, as the industry seeks to reach a more diverse population.

Crescendo stated that it would use the investment received to build software tools that would be used by clients to research the longitudinal effects of treatments and to track outcomes over time.